Summary
Economic analyses, which can be either descriptive or evaluative, can help to ensure that healthcare resources are used effectively. Most studies of diabetes mellitus have been descriptive and have used the cost-of-illness methodology, which estimates the burden of a disease to society. This method provides an estimate of the direct, indirect and intangible costs of a disease or illness. Methodological problems are mainly related to the measurement of indirect costs and even to whether they should be included at all. Existing studies that have measured the direct costs of non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes) serve to highlight the difficulties involved in comparing costs between countries with different healthcare systems, and the importance of defining the study population and the sources of the costs. There is a lack of recent data on the costs of treating people who have diabetes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Songer TJ. The economic costs of NIDDM. Diabetes Metab Rev 1992; 8: 389–404
Rice DP. Estimating the costs of illness. Health Economic Series, PHS Publ. no 947–6. Washington: Government Printing Office, 1966
Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Memorial Fund Q/Health Soc 1982; 60: 429–62
Rice DP. Cost of illness studies; fact or fiction? Lancet 1994; 344: 1519–20
Drummond M. Cost of illness studies. A major headache? PharmacoEconomics 1992; 2: 1–4
Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993; 26: 29–42
Laing W, Williams R. Diabetes. A model for health care management. Office of Health Economics, London, 1989
Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–10
Leese B. The cost of diabetes and its complications. Soc Sci Med 1992; 35: 1303–10
Davey PJ, Leeder SR. The cost of illness studies. Med J Aust 1993; 158: 583–4
Shiell A, Gerard K, Donaldson C. Cost of illness studies; an aid to decision making? Health Policy 1987; 8: 317–23
Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57–75
Robinson JC. Philosophical origins of the economic valuation of life. Milbank Q 1986; 64: 133–55
Davey PJ, Leeder SR. The cost of migraine. More than just a headache. PharmacoEconomics 1992; 2: 5–7
Brazier J, Jeavons R. The economics of diabetes care. In: Bradley C, Home P, Christie M, editors. The technology of diabetes care. Harwood Academic Publishers, Chur, 1991: 203–14
Jonsson B. Economic evaluation of health care technologies. Acta Endocrinologica 1993; 128 Suppl. 2: 50–4
Hodgson TA. Cost of illness studies; no aid to decision making? Health Policy 1989; 11: 57–60
Oklahoma State Department of Health. Diabetes mellitus — its economic impact. J Okla State Med Assoc 1991; 84: 30
Roesler J, Bishop D, Walseth J. Economic cost of diabetes mellitus-Minnesota, 1988. Morb Mortal Wkly Rep 1991; 40: 229–31
American Diabetes Assoc. Direct and indirect costs of diabetes in the US in 1987. Washington DC: American Diabetes Assoc, 1988
Entmacher PS, Sinnock P, Bostic E, et al. Diabetes in America. NIH Publication [no. 85–1468]. Bethesda: US Dept. of Health and Human Services, NIH, 1985
Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabet Med 1989; 6: 164–70
Herman W, Teutsch SM, Geiss LS. Diabetes mellitus. In: Ambler RW, Dull HB, editors. Closing the gap: the burden of unnecessary illness. Oxford: OUP, 1987
McKendry JBR. Direct costs of diabetes care; a survey in Ottawa, Ontario 1986. Can J Public Health 1989; 80: 124–8
Jonsson B. Diabetes — the cost of illness and the cost of control. Acta Med Scand 1983; 671 Suppl.: 19–27
Alexander WD. Diabetes care in a UK health region; activity, facilities and costs. Diabet Med 1988; 5: 577–81
Persson U. The economics of diabetes — a review. IHE Working Paper 1989: 3
Triomphe A, Flori Y-A, Lanoe J-L. The costs of diabetes to society and the individual. In: Williams R, Papoz L, Fuller J, editors. Diabetes in Europe. John Libbey & Co. Ltd, London, 1993: 153–60
Nabarro JDN. Diabetes in the United Kingdom; some facts and figures. Diabet Med 1988; 5: 816–22
Rubin RJ, Altman WM, Mendelson DN. Health care expenditure for people with diabetes mellitus 1992. J Clin Endocrinol Metab 1994; 78: 809A-809F
Phillips DE, Mann JI. Diabetes — inpatient utilisation, costs and data availability Dunedin 1985–9. NZ Med J 1992; 105: 313–5
Huse DM, Oster G, Killen AR, et al. The economic costs of non insulin dependent diabetes mellitus. JAMA 1989: 262: 2708–13
Colditz GA. Economic costs of obesity. Am J Clin Nutr 1992; 55: 503S-7S
Weinberger M, Cowper PA, Kirkman MS, et al. Economic impact of diabetes mellitus in the elderly. Clin Geriatr Med 1990; 6: 959–70
Gagliardino JJ, Olivera EM, Barragan H, et al. A simple economic evaluation model for selecting diabetes health care strategies. Diabet Med 1993; 10: 351–4
Triomphe A, Flori Y-A, Costagliola D, et al. The cost of diabetes in France. Health Policy 1988; 9: 39–48
Damsgaard EMS. Known diabetes and fasting hyperglycaemia in the elderly. Dan Med Bull 1990; 37: 530–46
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leese, B. Economic Evaluations of Type II Diabetes. Pharmacoeconomics 8 (Suppl 1), 23–27 (1995). https://doi.org/10.2165/00019053-199500081-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199500081-00006